L59 TGF-β LAP degradation products serve as a promising blood biomarker for liver fibrogenesis in mice

[1]  Y. Izumi,et al.  Eicosapentaenoic Acid Ameliorates Non-Alcoholic Steatohepatitis in a Novel Mouse Model Using Melanocortin 4 Receptor-Deficient Mice , 2015, PloS one.

[2]  Z. Ben‐Ari,et al.  [Non-invasive assessment of liver fibrosis]. , 2015, Harefuah.

[3]  G. Nguyen,et al.  Non-invasive diagnosis of advanced fibrosis and cirrhosis. , 2014, World journal of gastroenterology.

[4]  K. Iwaisako,et al.  Origin of myofibroblasts in the fibrotic liver in mice , 2014, Proceedings of the National Academy of Sciences.

[5]  Y. Koyama,et al.  The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies , 2014, Front. Pharmacol..

[6]  S. Friedman,et al.  LAP degradation product reflects plasma kallikrein-dependent TGF-β activation in patients with hepatic fibrosis , 2014, SpringerPlus.

[7]  S. Kojima,et al.  Neovessel formation promotes liver fibrosis via providing latent transforming growth factor-β. , 2014, Biochemical and biophysical research communications.

[8]  S. Yokoyama,et al.  HCV NS3 protease enhances liver fibrosis via binding to and activating TGF-β type I receptor , 2013, Scientific Reports.

[9]  S. Dooley,et al.  TGF-β in progression of liver disease , 2011, Cell and Tissue Research.

[10]  T. Walz,et al.  Latent TGF-β structure and activation , 2011, Nature.

[11]  W. Jochum,et al.  Characterization of time‐related changes after experimental bile duct ligation , 2008, The British journal of surgery.

[12]  S. Friedman,et al.  Mechanisms of hepatic fibrogenesis. , 2008, Gastroenterology.

[13]  H. Friess,et al.  Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. , 2008, Journal of hepatology.

[14]  Y. Inagaki,et al.  Emerging insights into Transforming growth factor β Smad signal in hepatic fibrogenesis , 2007, Gut.

[15]  D. Brenner,et al.  Erratum: Liver fibrosis (Journal of Clinical Investigation (2005) 115 (209-218) DOI:10.1172/JCI200524282) , 2005 .

[16]  A. Gressner,et al.  Adenoviral expression of a transforming growth factor-β1 antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats , 2003, BMC gastroenterology.

[17]  M. Sakaguchi,et al.  Establishment of an Immortalized Human Hepatic Stellate Cell Line to Develop Antifibrotic Therapies , 2003, Cell transplantation.

[18]  B. Olson,et al.  Inhibition of Transforming Growth Factor (TGF)- 1–Induced Extracellular Matrix with a Novel Inhibitor of the TGF- Type I Receptor Kinase Activity: SB-431542 , 2002 .

[19]  J. Seyer,et al.  Regulation of TGFβ gene expression in rat liver intoxicated with carbon tetrachloride , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  R. Coffey,et al.  Hepatic processing of transforming growth factor beta in the rat. Uptake, metabolism, and biliary excretion. , 1987, The Journal of clinical investigation.

[21]  R. Pierce,et al.  Increased procollagen mRNA levels in carbon tetrachloride-induced liver fibrosis in rats. , 1987, The Journal of biological chemistry.

[22]  S. Tanase,et al.  Plasma clearance of intravenously injected aspartate aminotransferase isozymes: Evidence for preferential uptake by sinusoidal liver cells , 1985, Hepatology.

[23]  D. Knook,et al.  Fat-storing cells of the rat liver. Their isolation and purification. , 1982, Experimental cell research.

[24]  R. Brentani,et al.  Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections , 1979, The Histochemical Journal.

[25]  D. Rifkin,et al.  7 TGF-β Bioavailability: Latency, Targeting, and Activation , 2008 .

[26]  R. Bataller,et al.  Amendment history : Corrigendum ( April 2005 ) Liver fibrosis Ramón Bataller , 2018 .